← Leaderboards
Mark A Jacobson
University Of California San Francisco
$6,824,928
Attributed
$6,824,928
Total exposure
25
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $562.7K · FY2005–08$1M$750K$500K$250K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$6,824,928 · 25
By mechanism
U01$3,414,433 · 1
R01$1,537,472 · 2
R21$840,617 · 2
P30$646,477 · 1
M01$383,889 · 17
P41$2,040 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Thomas J. Coates$58,121,154
- Robert Adron Harris$33,954,196
- Elena Fuentes-Afflick$394,238
- Gay Becker$5,834,595
- Stephen G Lisberger$23,481,717
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHiv InfectionsAids TherapyHuman Therapy EvaluationProtease InhibitorClinical Trial Phase IPharmacokineticsCombination ChemotherapyNelfinavirDrug InteractionsMycobacterium AviumOpportunistic InfectionsRitonavirSaquinavirAidsEfavirenzLamivudineZidovudineInterleukin 12CytomegalovirusCytokineImmunomodulatorsFlow Cytometry
Grant awards (80)
HIV Epitope Specific T Cell Responses and Control of HIV Replication$189,354
R21 · FY2008 · AI · contact PI
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis$189,263
R21 · FY2008 · EY · contact PI
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis$231,125
R21 · FY2007 · EY · contact PI
HIV Epitope Specific T Cell Responses and Control of HIV Replication$230,875
R21 · FY2007 · AI · contact PI
THE ROLE OF PROTEIN LOOP FLEXIBILITY IN SUBSTRATE BINDING$1,012
P41 · FY2006 · RR · contact PI
ADJUVANT RHIL-12 WITH A CYTOMEGALOVIRUS$300,944
M01 · FY2005 · RR
CMV Immune Response &Long-Term Outcome of CMV Retinitis$259,219
R01 · FY2005 · EY
AACTG 5079: PHYSIOLOGIC TESTOSTERONE$1,517
M01 · FY2005 · RR
THE ROLE OF PROTEIN LOOP FLEXIBILITY IN SUBSTRATE BINDING$1,028
P41 · FY2005 · RR
CMV Immune Response &Long-Term Outcome of CMV Retinitis$378,750
R01 · FY2004 · EY
Adjunct rhIL-12 enhance THI response to viral vaccine?$103,682
R01 · FY2004 · AI
ADJUVANT RHIL-12 WITH A CYTOMEGALOVIRUS$49,461
M01 · FY2004 · RR
ACTG 5077: HAART/HIV compartments$9,819
M01 · FY2004 · RR
AACTG A5082: Metformin/ Rosiglitazone$9,002
M01 · FY2004 · RR
A5159: HIV protease inhibitors and calcium channel blockers$5,727
M01 · FY2004 · RR
AACTG 5079: Physiologic testosterone$5,727
M01 · FY2004 · RR
Adjunct rhIL-12 enhance THI response to viral vaccine?$291,014
R01 · FY2003 · AI
Adjunct rhIL-12 enhance THI response to viral vaccine?$504,807
R01 · FY2002 · AI
DMP-266 OR NFV PLUS COMBIVIR AND INDINAVIR IN HIV$0
M01 · FY2002 · RR
SALVAGE ANTIRETROVIRAL THERAPY FOR HIV+ PATIENTS$0
M01 · FY2002 · RR
HIV PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV+ SUBJECTS$0
M01 · FY2002 · RR
QUADRUPLE DRUG TREATMENT WITH 3TC/ZDV PLUS ABC PLUS APV IN HIV INFECTION$0
M01 · FY2002 · RR
DISCONTINUING THERAPY FOR DISSEMINATED MAC$0
M01 · FY2002 · RR
QUADRUPLE DRUG TREATMENT WITH 3TC/ZDV PLUS ABC PLUS APV IN HIV INFECTION$0
M01 · FY2002 · RR
INTERACTION BETWEEN PI AND LIPID LOWERING AGENTS$0
M01 · FY2002 · RR
HIV PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV+ SUBJECTS$0
M01 · FY2002 · RR
PHASE I TRIAL OF IL-12 IN HIV INFECTED SUBJECTS$0
M01 · FY2002 · RR
AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2002 · RR
PHASE I TRIAL OF IL-12 IN HIV INFECTED SUBJECTS$0
M01 · FY2002 · RR
SALVAGE ANTIRETROVIRAL THERAPY FOR HIV+ PATIENTS$0
M01 · FY2002 · RR
PI AND NRTI IN HIV THERAPY$0
M01 · FY2002 · RR
INTERACTION BETWEEN PI AND LIPID LOWERING AGENTS$0
M01 · FY2002 · RR
PI AND NRTI IN HIV THERAPY$0
M01 · FY2002 · RR
DMP-266 OR NFV PLUS COMBIVIR AND INDINAVIR IN HIV$0
M01 · FY2002 · RR
DISCONTINUING THERAPY FOR DISSEMINATED MAC$0
M01 · FY2002 · RR
AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2002 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,729,811
U01 · FY2001 · AI
CORE--CLINICAL$165,355
P30 · FY2001 · MH
CORE--CLINICAL$131,864
P30 · FY2001 · MH
DISCONTINUING THERAPY FOR DISSEMINATED MAC$0
M01 · FY2001 · RR
PHASE I TRIAL OF IL-12 IN HIV INFECTED SUBJECTS$0
M01 · FY2001 · RR
PI AND NRTI IN HIV THERAPY$0
M01 · FY2001 · RR
SALVAGE ANTIRETROVIRAL THERAPY FOR HIV+ PATIENTS$0
M01 · FY2001 · RR
HIV PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV+ SUBJECTS$0
M01 · FY2001 · RR
INTERACTION BETWEEN PI AND LIPID LOWERING AGENTS$0
M01 · FY2001 · RR
QUADRUPLE DRUG TREATMENT WITH 3TC/ZDV PLUS ABC PLUS APV IN HIV INFECTION$0
M01 · FY2001 · RR
DMP-266 OR NFV PLUS COMBIVIR AND INDINAVIR IN HIV$0
M01 · FY2001 · RR
AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2001 · RR
ADULT AIDS CLINICAL TRIALS UNIT$1,684,622
U01 · FY2000 · AI
CORE--CLINICAL$349,258
P30 · FY2000 · MH
TRIAL TO EVALUATE TOLERABILITY, ANTI CMV ACTIVITY/PHARMACOKINETICS OF 1263W94$564
M01 · FY2000 · RR
SAFETY, TOLERANCE AND ACTIVITY ON PLASMA VIREMIA OF SCH 52000 IN HIV$564
M01 · FY2000 · RR
ACTG 387: PAIRED COMBINATIONS OF NELFINAVIR, RITONAVIR, &SAQUINAVIR$564
M01 · FY2000 · RR
PI AND NRTI IN HIV THERAPY$0
M01 · FY2000 · RR
DISCONTINUING THERAPY FOR DISSEMINATED MAC$0
M01 · FY2000 · RR
HIV PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV+ SUBJECTS$0
M01 · FY2000 · RR
HIV PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV+ SUBJECTS$0
M01 · FY2000 · RR
QUADRUPLE DRUG TREATMENT WITH 3TC/ZDV PLUS ABC PLUS APV IN HIV INFECTION$0
M01 · FY2000 · RR
PHASE I TRIAL OF IL-12 IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
HIV PROTEASE INHIBITORS AND METHADONE METABOLISM IN HIV+ SUBJECTS$0
M01 · FY2000 · RR
PI AND NRTI IN HIV THERAPY$0
M01 · FY2000 · RR
AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2000 · RR
SALVAGE ANTIRETROVIRAL THERAPY FOR HIV+ PATIENTS$0
M01 · FY2000 · RR
DMP-266 OR NFV PLUS COMBIVIR AND INDINAVIR IN HIV$0
M01 · FY2000 · RR
AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2000 · RR
INTERACTION BETWEEN PI AND LIPID LOWERING AGENTS$0
M01 · FY2000 · RR
SALVAGE ANTIRETROVIRAL THERAPY FOR HIV+ PATIENTS$0
M01 · FY2000 · RR
PI AND NRTI IN HIV THERAPY$0
M01 · FY2000 · RR
INTERACTION BETWEEN PI AND LIPID LOWERING AGENTS$0
M01 · FY2000 · RR
DMP-266 OR NFV PLUS COMBIVIR AND INDINAVIR IN HIV$0
M01 · FY2000 · RR
DISCONTINUING THERAPY FOR DISSEMINATED MAC$0
M01 · FY2000 · RR
INTERACTION BETWEEN PI AND LIPID LOWERING AGENTS$0
M01 · FY2000 · RR
QUADRUPLE DRUG TREATMENT WITH 3TC/ZDV PLUS ABC PLUS APV IN HIV INFECTION$0
M01 · FY2000 · RR
DMP-266 OR NFV PLUS COMBIVIR AND INDINAVIR IN HIV$0
M01 · FY2000 · RR
PHASE I TRIAL OF IL-12 IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
QUADRUPLE DRUG TREATMENT WITH 3TC/ZDV PLUS ABC PLUS APV IN HIV INFECTION$0
M01 · FY2000 · RR
SALVAGE ANTIRETROVIRAL THERAPY FOR HIV+ PATIENTS$0
M01 · FY2000 · RR
AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS$0
M01 · FY2000 · RR
PHASE I TRIAL OF IL-12 IN HIV INFECTED SUBJECTS$0
M01 · FY2000 · RR
DISCONTINUING THERAPY FOR DISSEMINATED MAC$0
M01 · FY2000 · RR